| Literature DB >> 35220959 |
Abstract
BACKGROUND: To investigate the relationship between tumor deposits (TDs) with the clinicopathological characteristics tumor-infiltrating lymphocytes (TILs) and prognosis of gastric cancer. Further analysis was done on the relationship between the number and maximum diameter of TDs with the clinicopathological characteristics and prognosis of gastric cancer.Entities:
Keywords: Prognosis; Tumor deposits; Tumor-infiltrating lymphocytes
Mesh:
Year: 2022 PMID: 35220959 PMCID: PMC8883644 DOI: 10.1186/s12957-022-02507-3
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Fig. 1An example of a tumor deposit (TD) of gastric cancer to show the pathological features. Tumor deposits (TDs) were clearly defined as discrete tumor nodules within the lymphatic drainage area of primary cancer and without identifiable lymph node tissue or identifiable vascular or neural structures
Association between tumor deposits clinicopathologic characteristics of gastric cancer.
| TDs+ | TDs− | ||
|---|---|---|---|
| Sex | |||
| Male | 65 | 196 | 0.033 |
| Female | 16 | 92 | |
| Age, years | |||
| ≤ 60 | 27 | 98 | 0.907 |
| > 60 | 54 | 190 | |
| Histologic grade | |||
| Undifferentiated | 69 | 224 | 0.145 |
| Differentiated | 12 | 64 | |
| Lauren classification | |||
| Diffuse type | 41 | 152 | 0.241 |
| Mixed type | 27 | 72 | |
| Intestines type | 13 | 64 | |
| LVI | |||
| Yes | 77 | 171 | 0.000 |
| No | 4 | 117 | |
| PNI | |||
| Yes | 71 | 152 | 0.000 |
| No | 10 | 136 | |
| MMR | |||
| pMMR | 76 | 253 | 0.126 |
| dMMR | 5 | 35 | |
| pT stage | |||
| T1 | 0 | 60 | 0.000 |
| T2 | 2 | 46 | |
| T3 | 14 | 80 | |
| T4 | 65 | 102 | |
| pN stage | |||
| N0 | 2 | 102 | 0.000 |
| N1 | 4 | 64 | |
| N2 | 14 | 51 | |
| N3 | 61 | 71 | |
| pM stage | |||
| M0 | 74 | 288 | 0.000 |
| M1 | 7 | 0 | |
| Clinical stage | |||
| I | 0 | 73 | 0.000 |
| II | 6 | 88 | |
| III | 68 | 127 | |
| IV | 7 | 0 | |
LVI lymphovascular invasion, PNI perineural invasion, MMR mismatch repair gene, pMMR proficient mismatch repair, dMMR deficient mismatch repair, TDs tumor deposits
Fig. 2Kaplan-Meier curves for tumor deposits. A Disease-free survival (DFS). B Cancer-specific survival (CSS). C Overall survival (OS). P < 0.05
Cox multivariate regression analysis of disease-free survival, cancer-specific survival, and overall survival correlation of tumor deposits
| DFS | CSS | OS | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | ||||
| TDs | 0.571 (0.353–0.923) | 0.022 | 0.464 (0.302–0.713) | 0.000 | 0.538 (0.356–0.814) | 0.003 |
| Age, years | – | – | – | – | 0.638 (1.089–2.462) | 0.018 |
| Histologic grade | – | – | 1.040 (0.444–2.433) | 0.929 | 1.198 (0.540–2.659) | 0.657 |
| Lauren classification | – | – | 0.610 | 0.446 | ||
| Lauren (1) | 0.668 (0.268–1.663) | 0.385 | 0.579 (0.248– | 0.207 | ||
| Lauren (2) | 0.863 (0.311–2.399) | 0.778 | 1.354) 0.688 (0.264–1.792) | 0.444 | ||
| LVI | 0.549 (0.207–1.454) | 0.228 | 0.960 (0.392–2.348) | 0.929 | 0.940 (0.404–2.184) | 0.885 |
| PNI | 0.511 (0.259–1.009) | 0.053 | 0.599 (0.324–1.105) | 0.101 | 0.685 (0.387–1.214) | 0.195 |
| pT stage | 0.353 | 0.019 | 0.009 | |||
| T(1) | 0.703 (0.119–4.158) | 0.698 | 0.290 (0.021–3.940) | 0.352 | 1.023 (0.162–6.454) | 0.981 |
| T(2) | 0.641 (0.091–4.519) | 0.655 | 2.000 (0.134–29.774) | 0.615 | 2.879 (0.312–26.583) | 0.351 |
| T(3) | 1.070 (0.144–7.925) | 0.947 | 4.142 (0.269–63.863) | 0.309 | 6.655 (0.700–63.284) | 0.099 |
| pN stage | 0.590 | 0.126 | 0.078 | |||
| N(1) | 0.921 (0.274–3.101) | 0.895 | 1.439 (0.406–5.106) | 0.573 | 1.312 (0.404–4.262) | 0.651 |
| N(2) | 0.589 (0.137–2.523) | 0.476 | 1.120 (0.241–5.205) | 0.885 | 1.025 (0.246–4.270) | 0.973 |
| N(3) | 0.847 (0.200–3.586) | 0.822 | 2.117 (0.476–9.409) | 0.325 | 2.022 (0.506–8.075) | 0.319 |
| Clinical stage | 0.563 | 0.442 | 0.299 | |||
| Clinical stage (1) | 2.258 (0.297–17.150) | 0.431 | 0.608 (0.037–9.896) | 0.727 | 0.492 (0.058–4.183) | 0.516 |
| Clinical stage (2) | 4.746 (0.335–67.150) | 0.249 | 1.029 (0.037–28.548) | 0.986 | 0.775 (0.054–11.212) | 0.852 |
| Clinical stage (3) | 2.698 (0.095–76.460) | 0.561 | 1.901 (0.060–60.743) | 0.716 | 1.559 (0.092–26.538) | 0.759 |
LVI, lymphovascular invasion; PNI, perineural invasion; TDs, tumor deposits
Fig. 3Kaplan-Meier curves for number of tumor deposits. A Disease-free survival (DFS). B Cancer-specific survival (CSS). C Overall survival (OS). P < 0.05
Fig. 4Kaplan-Meier curves for size of tumor deposit. A Disease-free survival (DFS). B Cancer-specific survival (CSS). C Overall survival (OS). P > 0.05
Fig. 5Expression of gastric cancer tumor-infiltrating lymphocytes. Expression of tumor-infiltrating lymphocytes. A and C Low-to-moderate tumor-infiltrating lymphocytes. B and D High tumor-infiltrating lymphocytes. (HE, hematoxylin and eosin × 40)
Correlation of tumor deposit and tumor-infiltrating lymphocytes
| TILs | |||
|---|---|---|---|
| Low-medium | High | ||
| TDs+ | 74 | 7 | 0.000 |
| TDs− | 205 | 83 |
TDs tumor deposits, TILs tumor-infiltrating lymphocytes